



Published in final edited form as:

*J Perinat Med.* 2019 July 26; 47(5): 516–527. doi:10.1515/jpm-2019-0003.

## The earlier the gestational age, the greater the intensity of the intra-amniotic inflammatory response in women with preterm premature rupture of membranes and amniotic fluid infection by *Ureaplasma* species

Kyung Joon OH, MD, PhD<sup>1,2</sup>, Roberto ROMERO, MD, DMedSci<sup>3,4,5,6</sup>, Jee Yoon PARK, MD<sup>1,2</sup>, Joon-Seok HONG, MD, PhD<sup>1,2</sup>, Bo Hyun YOON, MD, PhD<sup>1</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea;

<sup>2</sup>Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam-si, Korea;

<sup>3</sup>Perinatology Research Branch, NICHD/NIH/DHHS, Bethesda, Maryland, USA, and Detroit, Michigan, USA;

<sup>4</sup>Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, USA;

<sup>5</sup>Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, USA;

<sup>6</sup>Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, USA.

### Abstract

**Objective**—To determine the relationship between the intensity of the intra-amniotic inflammatory response and the gestational age at the time of diagnosis in cases with preterm premature rupture of membranes (PROM) and intra-amniotic infection caused by *Ureaplasma* spp.

**Methods**—A retrospective cohort study was conducted which included 71 women with preterm PROM and a positive amniotic fluid culture with *Ureaplasma* spp. Women with mixed intra-amniotic infections were excluded. The study population was classified into 3 groups according to gestational age: group 1, <26 weeks (extreme preterm PROM, n=17); group 2, 26.0–33.9 weeks (moderate preterm PROM, n=39); group 3, 34.0–36.9 weeks (late preterm PROM, n=15). The intensity of the intra-amniotic and maternal inflammatory response was compared among 3 groups. The intensity of the intra-amniotic inflammatory response was assessed by the concentration of amniotic fluid matrix metalloproteinase-8 (MMP-8) and white blood cell (WBC) count. The maternal inflammatory response was assessed by the concentration of C-reactive protein (CRP) and WBC count in maternal blood at the time of amniocentesis.

**Correspondence to:** Bo Hyun Yoon, MD, PhD, Professor, Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, Korea, 03080, Tel: 82-2-2072-2826/Fax: 82-2-762-3599, yoonbh@snu.ac.kr.

**Conflicts of interest:** The authors report no conflict of interest.

**Results**—1) The median values of amniotic fluid MMP-8 concentration and WBC count were the highest in extreme preterm PROM group and the lowest in the late preterm PROM group ( $P < 0.001$  and  $P=0.01$ , respectively); 2) the intensity of the maternal inflammatory response measured by maternal blood WBC count and CRP concentration was not significantly associated with gestational age at the time of diagnosis.

**Conclusion**—The earlier the gestational age at the time of PROM, the higher the intensity of the intra-amniotic inflammatory response in women with preterm PROM and intra-amniotic infection caused by *Ureaplasma* spp.

### Keywords

*Ureaplasma*; preterm premature rupture of membranes; microbial invasion of amniotic cavity; intra-amniotic inflammation; preterm labor; chorioamnionitis; prematurity; intra-amniotic infection; matrix metalloproteinase-8

## Introduction

*Ureaplasma* spp. are the most common microorganisms isolated from the amniotic fluid of women with preterm premature rupture of membranes (PROM) [1–14], preterm labor with intact membranes [15–17], acute cervical insufficiency [18–20], clinical chorioamnionitis at preterm [21] and term [22], PROM at term [23], and idiopathic vaginal bleeding [24].

A strong body of evidence supports that intra-amniotic infection with *Ureaplasma* spp. is associated with a robust host response in the fetal, amniotic, and maternal compartments [4, 6, 9, 16, 25–27] and that these organisms are associated with neonatal morbidity including neonatal bacteremia [28, 29], intraventricular hemorrhage [30, 31], chronic lung disease [32–36], meningitis [37], and adverse neuromotor development [38].

*Ureaplasma* spp. are frequently detected in amniotic fluid of asymptomatic women at early mid-trimester [39–41], which are often associated with preterm delivery, but not in all cases [40, 41]. These findings suggest that not only microbial invasion of the amniotic cavity but also the host response to microorganisms may be an important factor in determining the outcome of pregnancy.

Previous studies showed that the lower the gestational age, the higher the frequency of intra-amniotic infection and an intra-amniotic inflammation in symptomatic women with preterm PROM [42–44], and preterm labor [45, 46]. We hypothesized that the earlier the gestational age of PROM, the more intense the host-inflammatory response in women with intra-amniotic infection by *Ureaplasma* spp.

The purpose of this study was to determine the relationship between the intensity of intra-amniotic inflammation response and the gestational age in women with preterm PROM and intra-amniotic infection caused by *Ureaplasma* spp.

## Material and Methods

### Study Design

This study population consisted of 71 consecutive patients admitted to Seoul National University Hospital between 1993 and 2012 with the diagnosis of preterm PROM (<37 weeks of gestation) who met the following criteria: (1) singleton pregnancy; (2) amniotic fluid obtained for microbiologic studies by transabdominal amniocentesis or at the time of cesarean delivery, and (3) proven intra-amniotic infection by *Ureaplasma* spp. using cultivation techniques. Women with a mixed intra-amniotic infection (*Ureaplasma* spp. and other microorganisms) were excluded.

Patients were divided into 3 groups according to the gestational age at amniocentesis: group 1, gestational age <26 weeks (extreme preterm, n=17); group 2, gestational age between 26.0–33.9 weeks (moderate preterm, n=39); group 3, gestational age between 34.0–36.9 weeks (late preterm, n=15). The intensity of the intra-amniotic inflammatory response was determined by the amniotic fluid matrix metalloproteinase-8 (MMP-8) concentration and white blood cell (WBC) count, and that of the maternal inflammatory response was determined by C-reactive protein (CRP) and WBC count in maternal blood at the time of amniocentesis. Amniocentesis is routinely offered to all patients who are admitted with the diagnosis of preterm PROM for microbiologic studies and/or assessment of fetal lung maturity. Retrieval of amniotic fluid and maternal blood was performed after written informed consent was obtained.

We followed the ethical standards for human experimentation established in the Declaration of Helsinki. The Institutional Review Board of Seoul National University Hospital approved the collection and use of these samples and information for research purposes. The University has a Federal Wide Assurance with the Office for Human Research Protection (OHRP) of the Department of Health and Human Services (DHHS) of the United States.

### Amniotic fluid analysis

Amniotic fluid was retrieved by transabdominal amniocentesis or at the time of cesarean delivery. The fluid was collected and transferred into commercially available culture media and transported immediately to the Department of Laboratory Medicine of our hospital and cultured for genital mycoplasmas (*Ureaplasma* spp. and *Mycoplasma hominis*) as well as aerobic and anaerobic bacteria. An aliquot of amniotic fluid was examined in a hemocytometer chamber to determine the WBC count. Fluid not used for clinical purposes was centrifuged and stored in polypropylene tubes at  $-70^{\circ}\text{C}$ . The stored amniotic fluid was analyzed for MMP-8, which was measured using a commercially available enzyme-linked immunosorbent assay (R&D Systems, Inc., Minneapolis, MN, USA). Each measurement was performed in duplicate. Intra- and inter-assay coefficients were <10% each. Intra-amniotic inflammation was defined as an elevated concentration of MMP-8 (>23 ng/mL), as previously reported [19, 42, 47–54].

## Diagnosis of chorioamnionitis and neonatal morbidity

Acute histologic chorioamnionitis was defined as the presence of acute inflammatory changes in the choriodecidua and amnion, respectively; acute funisitis was diagnosed by the presence of neutrophil infiltration into umbilical vessel walls or Wharton's jelly using criteria previously published [55–57]. Clinical chorioamnionitis was diagnosed in the presence of a maternal temperature of  $\geq 37.8^{\circ}\text{C}$  and  $\geq 2$  of the following criteria: (1) uterine tenderness; (2) malodorous vaginal discharge; (3) maternal leukocytosis (WBC count  $>15,000$  cells/ $\text{mm}^3$ ); (4) maternal tachycardia ( $>100$  beats/min); and (5) fetal tachycardia ( $>160$  beats/min) [22, 58–67]. Significant neonatal morbidity was defined as the presence of any of the following conditions: respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage (grade  $\geq$  II), proven congenital neonatal sepsis, and necrotizing enterocolitis. These conditions were diagnosed according to definitions previously described in detail [55].

## Statistical analysis

Non-parametric analyses were used. Proportions were compared using the Fisher's exact test. The Kruskal-Wallis test and Jonckheere-Terpstra test were used for comparison of continuous variables and linear-by-linear association was used for comparison of the proportions among the three groups. A P value  $< 0.05$  was considered as significant. SPSS 22.0 for Windows (IBM, Armonk, NY, USA) was used for statistical analyses.

## Results

A total of 73 patients met the inclusion criteria. Amniotic fluid was not available for MMP-8 determination in 2 cases; therefore, these patients were excluded from further analysis. Seventeen women comprised group 1 (extreme preterm PROM group, gestational age  $<26$  weeks), 39 comprised group 2 (moderate preterm PROM group, gestational age from 26.0 weeks to 33.9 weeks), and 15 comprised group 3 (late preterm PROM group, gestational age from 34.0 weeks to 36.9 weeks). Table 1 displays the clinical characteristics and pregnancy outcomes according to gestational age at amniocentesis. There were no significant differences in maternal age, parity, rate of cesarean delivery, antibiotics use and neonatal gender among the three groups. Gestational age at delivery and use of antenatal corticosteroids were significantly different among groups. The prevalence of clinical chorioamnionitis was highest in extreme preterm PROM group (12% [2/17]), followed by moderate preterm PROM group (5% [2/39]) and by late preterm PROM group (0% [0/15]). However, the difference was not statistically significant ( $P>0.1$ ).

Figure 1 shows the intensity of intra-amniotic inflammatory response assessed by the amniotic fluid MMP-8 concentrations according to the gestational age at amniocentesis. The median amniotic fluid MMP-8 concentration in extreme preterm PROM group was 714.6 ng/mL (interquartile range [IQR], 165.8–2681.2 ng/mL), which was significantly higher than that of moderate preterm PROM group (median: 157.7 ng/mL, IQR: 24.9–870.8 ng/mL) and that of late preterm PROM group (median: 24.0 ng/mL, IQR 1.8–272.3 ng/mL) ( $P<0.05$ , respectively).

Table 2 shows that the amniotic fluid MMP-8 concentrations and the WBC counts decrease as a function of advancing gestational age at the time of amniocentesis ( $P < .001$  for amniotic fluid MMP-8 concentrations and  $P = .010$  for amniotic fluid WBC count by Jonckheere-Terpstra test). Figure 2 shows the rate of intra-amniotic inflammation defined as amniotic fluid MMP-8 concentration of  $> 23$  ng/mL according to the gestational age at amniocentesis. The rate of intra-amniotic inflammation was 94% (16/17) in the extreme preterm PROM group, 80% [31/39] in moderate preterm PROM group, and 53% [8/15] in late preterm PROM group. It decreases with advancing gestational age ( $P = .002$  by linear by linear association).

Table 3 displays the maternal WBC counts and the CRP concentrations according to the gestational age at the time of amniocentesis. There were no significant differences in these maternal inflammatory markers among groups ( $P = 0.186$  for maternal blood WBC count and  $P = 0.146$  for serum CRP concentrations by Jonckheere-Terpstra test).

Table 4 presents the correlation between markers of amniotic fluid and a systemic maternal inflammatory response, and gestational age at amniocentesis. The intensity of the amniotic fluid inflammatory response markers was inversely correlated with gestational age ( $P < .001$  for amniotic fluid MMP-8 and  $P = .003$  for amniotic fluid WBC count). However, the maternal inflammatory markers were not significantly associated with gestational age at the time of amniocentesis ( $P = .103$  for maternal blood CRP and  $P = .055$  for maternal blood WBC count).

Table 5 shows the neonatal outcome according to gestational age at amniocentesis. The lower the gestational age, the higher the frequency of low Apgar scores of  $< 7$  for 1 and 5 minutes, neonatal death, and significant morbidity.

## Discussion

### Principal findings of this study

(1) The lower the gestational age at the time of PROM, the higher the intensity of the intra-amniotic inflammatory response in women with preterm PROM and intra-amniotic infection caused by *Ureaplasma* spp.; (2) the frequency of intra-amniotic inflammation was 94% (16/17) in the extreme preterm PROM group (gestational age  $< 26$  weeks), 80% (31/39) in the moderate preterm PROM group (gestational age between 26.0–33.9 weeks) and 53% (8/15) in the late preterm PROM group (gestational age between 34.0–36.9 weeks); 3) the intensity of the maternal inflammatory response was not significantly associated with gestational age at amniocentesis.

### Intra-amniotic infection by *Ureaplasma* spp.

*Ureaplasma* spp. are the most frequent isolates from amniotic fluid in patients with preterm labor [15–17, 68–70], preterm PROM [1–11], clinical chorioamnionitis [21, 22], acute cervical insufficiency [18, 20], and a short cervix [71]. Even in asymptomatic mid-trimester patients, isolation of *Ureaplasma* spp. is linked to early preterm delivery [40, 41, 72]. In a primate model of intra-amniotic infection, inoculation of *Ureaplasma* spp. in the amniotic fluid results in initiation of intra-amniotic pro-inflammatory cascade, and spontaneous

preterm birth [73, 74]. Previous studies showed that intra-amniotic infection caused by *Ureaplasma* spp. has a similar or more intense inflammatory response compared to that caused by other microorganisms [4, 9, 75].

Several studies based on culture methods showed that cervicovaginal colonization of these organisms is associated with preterm birth [76–81]. However, cervico-vaginal colonization of these organisms is found in 30–60% of pregnant women [76, 77, 79, 82] and there is no evidence that detection of *Ureaplasma* spp. in cervico-vaginal fluid can be helpful in preventing preterm birth. In our previous study [83], bacterial vaginosis but not a positive culture for genital mycoplasmas is a risk factor for spontaneous preterm birth. This is consistent with previous studies [79, 82]. Interestingly, about a half of *Trichomonas vaginalis* isolates from vaginal samples of patients with purulent vaginitis harbor intracellular genital *Mycoplasmas* including *M. hominis* and *Ureaplasma* spp. [84].

It is unclear why most intra-amniotic infections are caused by *Ureaplasma* spp. [7, 26]. In this process, it is thought that the host defense system, such as the cervical canal and cervical mucus, plays an important role [85–88]. A solid body of evidence indicates that a short cervical length is associated with intra-amniotic infection/inflammation [68, 71, 89–91] and development of spontaneous preterm birth [68, 90, 92–112]. A recent microbiome study has found considerable greater complexity in the placental membrane community [113–115]. Virulent microorganisms including *Escherichia coli* and *Enterobacter* spp. are frequently found and similar in abundance between term and preterm subjects with and without chorioamnionitis [114]. Of interest is that preterm subjects with severe chorioamnionitis had high abundances of *Ureaplasma* spp. and *Fusobacterium nucleatum* [114, 116]. In our previous study which was directed at twins, *Ureaplasma* spp. were found in both amniotic cavities in all cases with intra-amniotic infections with *Ureaplasma* spp. Contrariwise, most of other microorganisms were found only in presenting amniotic cavity [117]. Collectively, these findings suggest that *Ureaplasma* spp. could more easily cross the chorioamniotic membrane, thereby reaching the amniotic fluid than did other bacteria.

### **Host inflammatory response to intra-amniotic infection caused by *Ureaplasma* spp.**

In the current study, the intensity of the intra-amniotic inflammatory response was different in cases with intra-amniotic infections with *Ureaplasma* spp. as a function of gestational age. This may be due to a difference in inoculum size, the host's immunological response, timing and duration of infection, co-infected microorganisms and the presence or absence of any other inflammatory modifiers such as prior immune priming or viral exposure [118]. Previous studies showed that the inoculum size plays a role in determining the intensity of the inflammatory response [2, 119, 120]. Therefore, the differences in the host-inflammatory response may largely depend on the burden of these organisms. Another reason may be due to different host-microbe interactions. Some investigators have reported that host genetic background and racial disparity impact the disease outcome during intrauterine infection with *Ureaplasma* spp. [121, 122]. However, these findings cannot explain the result of the current study that the earlier the gestational age, the greater the intensity of the intra-amniotic inflammatory response in women with preterm PROM and intra-amniotic infections with *Ureaplasma* spp.

It is well-known that oxytocin play a central role in spontaneous human labor. Progesterone and estradiol are thought as the primary regulators of oxytocin receptor expression [123, 124]. However, expression of the oxytocin receptor is also regulated by interleukin (IL)-1 $\beta$ , IL-6, and tumor necrosis factor (TNF) in uterine smooth muscle cells [125–127]. Other investigators showed that IL-1 $\beta$  and TNF upregulate inflammation-related rapid genes [128], which regulate oxytocin receptor [129, 130]. The level of oxytocin receptor messenger RNA (mRNA) and oxytocin receptor in human myometrium at term is greater than that found in preterm myometrium [131]. Therefore, more intense inflammatory response may be required to induce labor at early gestation. Considering the survival of newborn, it may be more advantageous to maintain pregnancy in early preterm cases with mild infection/inflammation.

### **The maternal systemic and intrauterine local inflammation**

A strong body of evidence suggests that preterm birth is associated with maternal systemic inflammatory conditions such as appendicitis [132–135], acute pyelonephritis [136–138], influenza [139–141], and sepsis [142]. The rates of spontaneous preterm birth in such conditions are 5.1% in appendicitis [133], 10.3% in acute pyelonephritis [138], and 5–30% in influenza [139]. Of note, among pregnancies with appendectomy, the spontaneous preterm birth rate is associated with the gestational age at appendectomy (4.4% with gestational age <24 weeks; 7.5% with gestational age between 24–28 weeks and 9.1% with gestational age between 29–36 weeks) [133]. This finding supports the view that a more intense inflammatory response is required to induce spontaneous preterm labor at earlier gestational ages.

Most pregnant women deliver at term despite maternal infections such as appendicitis, acute pyelonephritis and influenza. By contrast, most patients with intra- amniotic infection and/or inflammation deliver preterm [2–4, 15, 17, 42, 45, 46, 143–145]. One of unexpected findings in the current study is that the intensity of maternal systemic inflammatory response was not associated with the gestational age at PROM. These findings suggest that the local inflammatory response has a more important role in spontaneous preterm birth than did maternal systemic inflammatory response.

Previous studies have shown that the analysis of maternal inflammatory markers may help predict intra-amniotic infection. However, this does not appear to have clinical utility compared to the assessment of amniotic cavity [146–148]. In a series of studies, the maternal concentration of inflammatory markers including IL-6 and CRP had a sensitivity of 56–79% and specificity of 59–77% in the identification of intra-amniotic infection [146–148]. Clinical chorioamnionitis based on maternal fever also has only 20–30% sensitivity to detect intra-amniotic infection [4, 147]. In the current study, only 25% of patients had an elevated maternal blood WBC count of > 15000 cells/mm<sup>3</sup>. Therefore, it is unlikely that analysis of maternal systemic inflammatory response is able to replace the evaluation of intra-amniotic infection and inflammatory response in women with preterm PROM [149].

## Strengths and limitations of the study

The strength of this study is that the relationship between the intensity of intra-amniotic inflammation and gestational age was analyzed in a relatively large population with intra-amniotic infections with *Ureaplasma* spp. A limitation of this study is that the intra-amniotic infection was determined by cultivation techniques. Therefore, some of the cases may have infections with other microorganisms not detected using cultivation techniques [17, 150].

## Conclusion

The most important clinical implication of our study is that the intra-amniotic inflammatory response varies as a function of gestational age at the time of PROM in women with intra-amniotic infection caused by *Ureaplasma* spp. Specifically, the earlier the gestational age at which PROM occurs, the more intense the intra-amniotic inflammatory response.

## Funding

This study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by Ministry of Science, ICT & Future Planning, Republic of Korea (2017R1A2B2007958); federal funds from NICHD/NIH/DHHS (HHSN27520130006C) and the Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice

*Kennedy Shriver* National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS).

## References

1. Gauthier DW, Meyer WJ. Comparison of gram stain, leukocyte esterase activity, and amniotic fluid glucose concentration in predicting amniotic fluid culture results in preterm premature rupture of membranes. *Am J Obstet Gynecol* 1992;167:1092–5. [PubMed: 1384334]
2. Romero R, Yoon BH, Mazor M, Gomez R, Gonzalez R, Diamond MP, et al. A comparative study of the diagnostic performance of amniotic fluid glucose, white blood cell count, interleukin-6, and gram stain in the detection of microbial invasion in patients with preterm premature rupture of membranes. *Am J Obstet Gynecol* 1993;169:839–51. [PubMed: 7694463]
3. Averbuch B, Mazor M, Shoham-Vardi I, Chaim W, Vardi H, Horowitz S, et al. Intra-uterine infection in women with preterm premature rupture of membranes: maternal and neonatal characteristics. *Eur J Obstet Gynecol Reprod Biol* 1995;62:25–9. [PubMed: 7493703]
4. Yoon BH, Romero R, Park JS, Chang JW, Kim YA, Kim JC, et al. Microbial invasion of the amniotic cavity with *Ureaplasma urealyticum* is associated with a robust host response in fetal, amniotic, and maternal compartments. *Am J Obstet Gynecol* 1998;179:1254–60. [PubMed: 9822511]
5. Rizzo G, Capponi A, Vlachopoulou A, Angelini E, Grassi C, Romanini C. Interleukin-6 concentrations in cervical secretions in the prediction of intrauterine infection in preterm premature rupture of the membranes. *Gynecol Obstet Invest* 1998;46:91–5. [PubMed: 9701687]
6. Yoon BH, Romero R, Kim M, Kim EC, Kim T, Park JS, et al. Clinical implications of detection of *Ureaplasma urealyticum* in the amniotic cavity with the polymerase chain reaction. *Am J Obstet Gynecol* 2000;183:1130–7. [PubMed: 11084554]
7. Goncalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. *Ment Retard Dev Disabil Res Rev* 2002;8:3–13. [PubMed: 11921380]
8. Berger A, Witt A, Haiden N, Kretzer V, Heinze G, Pollak A. Amniotic cavity cultures, blood cultures, and surface swabs in preterm infants--useful tools for the management of early-onset sepsis? *Journal of perinatal medicine* 2004;32:446–52. [PubMed: 15493724]
9. Oh KJ, Lee KA, Sohn YK, Park CW, Hong JS, Romero R, et al. Intraamniotic infection with genital mycoplasmas exhibits a more intense inflammatory response than intraamniotic infection with other



- microorganisms in patients with preterm premature rupture of membranes. *Am J Obstet Gynecol* 2010;203:211 e1–8. [PubMed: 20678747]
10. DiGiulio DB, Romero R, Kusanovic JP, Gomez R, Kim CJ, Seok KS, et al. Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. *Am J Reprod Immunol* 2010;64:38–57. [PubMed: 20331587]
  11. Musilova I, Andrys C, Drahosova M, Soucek O, Pliskova L, Jacobsson B, et al. Cervical fluid interleukin 6 and intra-amniotic complications of preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med* 2018;31:827–36. [PubMed: 28277919]
  12. Tchirikov M, Schlabritz-Loutsevitch N, Maher J, Buchmann J, Naberezhnev Y, Winarno AS, et al. Mid-trimester preterm premature rupture of membranes (PPROM): etiology, diagnosis, classification, international recommendations of treatment options and outcome. *Journal of perinatal medicine* 2018;46:465–88. [PubMed: 28710882]
  13. Revello R, Alcaide MJ, Dudzik D, Abehsera D, Bartha JL. Differential amniotic fluid cytokine profile in women with chorioamnionitis with and without funisitis. *J Matern Fetal Neonatal Med* 2016;29:2161–5. [PubMed: 26372455]
  14. Dudzik D, Revello R, Barbas C, Bartha JL. LC-MS-based metabolomics identification of novel biomarkers of chorioamnionitis and its associated perinatal neurological damage. *J Proteome Res* 2015;14:1432–44. [PubMed: 25620495]
  15. Romero R, Sirtori M, Oyarzun E, Avila C, Mazor M, Callahan R, et al. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. *Am J Obstet Gynecol* 1989;161:817–24. [PubMed: 2675611]
  16. Yoon BH, Chang JW, Romero R. Isolation of *Ureaplasma urealyticum* from the amniotic cavity and adverse outcome in preterm labor. *Obstet Gynecol* 1998;92:77–82. [PubMed: 9649098]
  17. DiGiulio DB, Romero R, Amogan HP, Kusanovic JP, Bik EM, Gotsch F, et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. *PLoS One* 2008;3:e3056. [PubMed: 18725970]
  18. Romero R, Gonzalez R, Sepulveda W, Brandt F, Ramirez M, Sorokin Y, et al. Infection and labor. VIII. Microbial invasion of the amniotic cavity in patients with suspected cervical incompetence: prevalence and clinical significance. *Am J Obstet Gynecol* 1992;167:1086–91. [PubMed: 1415396]
  19. Lee SE, Romero R, Park CW, Jun JK, Yoon BH. The frequency and significance of intraamniotic inflammation in patients with cervical insufficiency. *Am J Obstet Gynecol* 2008;198:633 e1–8. [PubMed: 18342290]
  20. Oh KJ, Lee SE, Jung H, Kim G, Romero R, Yoon BH. Detection of ureaplasmas by the polymerase chain reaction in the amniotic fluid of patients with cervical insufficiency. *Journal of perinatal medicine* 2010;38:261–8. [PubMed: 20192887]
  21. Oh KJ, Kim SM, Hong JS, Maymon E, Erez O, Panaitescu B, et al. Twenty-four percent of patients with clinical chorioamnionitis in preterm gestations have no evidence of either culture-proven intraamniotic infection or intraamniotic inflammation. *Am J Obstet Gynecol* 2017;216:604 e1–e11. [PubMed: 28257964]
  22. Romero R, Miranda J, Kusanovic JP, Chaiworapongsa T, Chaemsaitong P, Martinez A, et al. Clinical chorioamnionitis at term I: microbiology of the amniotic cavity using cultivation and molecular techniques. *Journal of perinatal medicine* 2015;43:19–36. [PubMed: 25720095]
  23. Romero R, Mazor M, Morrotti R, Avila C, Oyarzun E, Insunza A, et al. Infection and labor. VII. Microbial invasion of the amniotic cavity in spontaneous rupture of membranes at term. *Am J Obstet Gynecol* 1992;166:129–33. [PubMed: 1301006]
  24. Gomez R, Romero R, Nien JK, Medina L, Carstens M, Kim YM, et al. Idiopathic vaginal bleeding during pregnancy as the only clinical manifestation of intrauterine infection. *J Matern Fetal Neonatal Med* 2005;18:31–7. [PubMed: 16105789]
  25. Yoon BH, Romero R, Lim JH, Shim SS, Hong JS, Shim JY, et al. The clinical significance of detecting *Ureaplasma urealyticum* by the polymerase chain reaction in the amniotic fluid of patients with preterm labor. *Am J Obstet Gynecol* 2003;189:919–24. [PubMed: 14586326]

26. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. *Science* 2014;345:760–5. [PubMed: 25124429]
27. Revello R, Alcaide MJ, Abehsera D, Martin-Camean M, Sousa EFGM, Alonso-Luque B, et al. Prediction of chorioamnionitis in cases of intraamniotic infection by ureaplasma urealyticum in women with very preterm premature rupture of membranes or preterm labour. *J Matern Fetal Neonatal Med* 2018;31:1839–44. [PubMed: 28502201]
28. Likitnukul S, Kusmiesz H, Nelson JD, McCracken GH Jr. Role of genital mycoplasmas in young infants with suspected sepsis. *J Pediatr* 1986;109:971–4. [PubMed: 3783341]
29. Goldenberg RL, Andrews WW, Goepfert AR, Faye-Petersen O, Cliver SP, Carlo WA, et al. The Alabama Preterm Birth Study: umbilical cord blood *Ureaplasma urealyticum* and *Mycoplasma hominis* cultures in very preterm newborn infants. *Am J Obstet Gynecol* 2008;198:43 e1–5. [PubMed: 18166302]
30. Viscardi RM, Hashmi N, Gross GW, Sun CC, Rodriguez A, Fairchild KD. Incidence of invasive ureaplasma in VLBW infants: relationship to severe intraventricular hemorrhage. *J Perinatol* 2008;28:759–65. [PubMed: 18596706]
31. Kasper DC, Mechtler TP, Bohm J, Petricevic L, Gleiss A, Spergser J, et al. In utero exposure to *Ureaplasma* spp. is associated with increased rate of bronchopulmonary dysplasia and intraventricular hemorrhage in preterm infants. *Journal of perinatal medicine* 2011;39:331–6. [PubMed: 21526978]
32. Cassell GH, Waites KB, Crouse DT, Rudd PT, Canupp KC, Stagno S, et al. Association of *Ureaplasma urealyticum* infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants. *Lancet* 1988;2:240–5. [PubMed: 2899235]
33. Sanchez PJ, Regan JA. *Ureaplasma urealyticum* colonization and chronic lung disease in low birth weight infants. *Pediatr Infect Dis J* 1988;7:542–6. [PubMed: 3174298]
34. Payne NR, Steinberg SS, Ackerman P, Chrenka BA, Sane SM, Anderson KT, et al. New prospective studies of the association of *Ureaplasma urealyticum* colonization and chronic lung disease. *Clin Infect Dis* 1993;17 Suppl 1:S117–21. [PubMed: 8399901]
35. Lowe J, Watkins WJ, Edwards MO, Spiller OB, Jacqz-Aigrain E, Kotecha SJ, et al. Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis. *Pediatr Infect Dis J* 2014;33:697–702. [PubMed: 24445836]
36. Viscardi RM, Kallapur SG. Role of *Ureaplasma Respiratory Tract Colonization* in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update. *Clin Perinatol* 2015;42:719–38. [PubMed: 26593075]
37. Hentschel J, Abele-Horn M, Peters J. *Ureaplasma urealyticum* in the cerebrospinal fluid of a premature infant. *Acta Paediatr* 1993;82:690–3. [PubMed: 8374221]
38. Berger A, Witt A, Haiden N, Kaider A, Klebermasz K, Fuiko R, et al. Intrauterine infection with *Ureaplasma* species is associated with adverse neuromotor outcome at 1 and 2 years adjusted age in preterm infants. *Journal of perinatal medicine* 2009;37:72–8. [PubMed: 18976044]
39. Horowitz S, Mazor M, Romero R, Horowitz J, Glezerman M. Infection of the amniotic cavity with *Ureaplasma urealyticum* in the midtrimester of pregnancy. *J Reprod Med* 1995;40:375–9. [PubMed: 7608879]
40. Gerber S, Vial Y, Hohlfeld P, Witkin SS. Detection of *Ureaplasma urealyticum* in second-trimester amniotic fluid by polymerase chain reaction correlates with subsequent preterm labor and delivery. *J Infect Dis* 2003;187:518–21. [PubMed: 12552439]
41. Perni SC, Vardhana S, Korneeva I, Tuttle SL, Paraskevas LR, Chasen ST, et al. *Mycoplasma hominis* and *Ureaplasma urealyticum* in midtrimester amniotic fluid: association with amniotic fluid cytokine levels and pregnancy outcome. *Am J Obstet Gynecol* 2004;191:1382–6. [PubMed: 15507969]
42. Shim SS, Romero R, Hong JS, Park CW, Jun JK, Kim BI, et al. Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes. *Am J Obstet Gynecol* 2004;191:1339–45. [PubMed: 15507963]

43. Romero R, Miranda J, Chaemsaitong P, Chaiworapongsa T, Kusanovic JP, Dong Z, et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med* 2015;28:1394–409. [PubMed: 25190175]
44. Kacerovsky M, Musilova I, Khatibi A, Skogstrand K, Hougaard DM, Tambor V, et al. Intraamniotic inflammatory response to bacteria: analysis of multiple amniotic fluid proteins in women with preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med* 2012;25:2014–9. [PubMed: 22519389]
45. Yoon BH, Romero R, Moon JB, Shim SS, Kim M, Kim G, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. *Am J Obstet Gynecol* 2001;185:1130–6. [PubMed: 11717646]
46. Combs CA, Gravett M, Garite TJ, Hickok DE, Lapidus J, Porreco R, et al. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. *Am J Obstet Gynecol* 2014;210:125 e1–e15. [PubMed: 24274987]
47. Park JS, Romero R, Yoon BH, Moon JB, Oh SY, Han SY, et al. The relationship between amniotic fluid matrix metalloproteinase-8 and funisitis. *Am J Obstet Gynecol* 2001;185:1156–61. [PubMed: 11717650]
48. Lee SE, Romero R, Jung H, Park CW, Park JS, Yoon BH. The intensity of the fetal inflammatory response in intraamniotic inflammation with and without microbial invasion of the amniotic cavity. *Am J Obstet Gynecol* 2007;197:294 e1–6. [PubMed: 17826426]
49. Lee J, Oh KJ, Yang HJ, Park JS, Romero R, Yoon BH. The importance of intra-amniotic inflammation in the subsequent development of atypical chronic lung disease. *J Matern Fetal Neonatal Med* 2009;22:917–23. [PubMed: 19718578]
50. Kim SM, Romero R, Lee J, Mi Lee S, Park CW, Shin Park J, et al. The frequency and clinical significance of intra-amniotic inflammation in women with preterm uterine contractility but without cervical change: do the diagnostic criteria for preterm labor need to be changed? *J Matern Fetal Neonatal Med* 2012;25:1212–21. [PubMed: 21999173]
51. Kim SM, Romero R, Park JW, Oh KJ, Jun JK, Yoon BH. The relationship between the intensity of intra-amniotic inflammation and the presence and severity of acute histologic chorioamnionitis in preterm gestation. *J Matern Fetal Neonatal Med* 2015;28:1500–9. [PubMed: 25184305]
52. Lee J, Romero R, Kim SM, Chaemsaitong P, Park CW, Park JS, et al. A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. *J Matern Fetal Neonatal Med* 2016;29:707–20. [PubMed: 26373262]
53. Kim SM, Romero R, Lee J, Chaemsaitong P, Docheva N, Yoon BH. Gastric fluid versus amniotic fluid analysis for the identification of intra-amniotic infection due to *Ureaplasma* species. *J Matern Fetal Neonatal Med* 2016;29:2579–87. [PubMed: 26631980]
54. Oh KJ, Park JY, Lee J, Hong JS, Romero R, Yoon BH. The combined exposure to intra-amniotic inflammation and neonatal respiratory distress syndrome increases the risk of intraventricular hemorrhage in preterm neonates. *Journal of perinatal medicine* 2018;46:9–20. [PubMed: 28672753]
55. Yoon BH, Romero R, Kim CJ, Jun JK, Gomez R, Choi JH, et al. Amniotic fluid interleukin-6: a sensitive test for antenatal diagnosis of acute inflammatory lesions of preterm placenta and prediction of perinatal morbidity. *Am J Obstet Gynecol* 1995;172:960–70. [PubMed: 7892891]
56. Kim CJ, Romero R, Chaemsaitong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. *Am J Obstet Gynecol* 2015;213:S29–52. [PubMed: 26428501]
57. Lee SE, Romero R, Kim CJ, Shim SS, Yoon BH. Funisitis in term pregnancy is associated with microbial invasion of the amniotic cavity and intra-amniotic inflammation. *J Matern Fetal Neonatal Med* 2006;19:693–7. [PubMed: 17127492]
58. Gibbs RS, Blanco JD, St Clair PJ, Castaneda YS. Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term. *J Infect Dis* 1982;145:1–8. [PubMed: 7033397]
59. Gibbs RS, Castillo MS, Rodgers PJ. Management of acute chorioamnionitis. *Am J Obstet Gynecol* 1980;136:709–13. [PubMed: 7355955]

60. Romero R, Chaemsaithong P, Korzeniewski SJ, Tarca AL, Bhatti G, Xu Z, et al. Clinical chorioamnionitis at term II: the intra-amniotic inflammatory response. *Journal of perinatal medicine* 2016;44:5–22. [PubMed: 25938217]
61. Kim SM, Romero R, Lee J, Chaemsaithong P, Lee MW, Chaiyasit N, et al. About one-half of early spontaneous preterm deliveries can be identified by a rapid matrix metalloproteinase-8 (MMP-8) bedside test at the time of mid-trimester genetic amniocentesis. *J Matern Fetal Neonatal Med* 2016;29:2414–22. [PubMed: 26643648]
62. Lee J, Romero R, Kim SM, Chaemsaithong P, Yoon BH. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM. *J Matern Fetal Neonatal Med* 2016;29:2727–37. [PubMed: 26441216]
63. Romero R, Chaemsaithong P, Docheva N, Korzeniewski SJ, Tarca AL, Bhatti G, et al. Clinical chorioamnionitis at term V: umbilical cord plasma cytokine profile in the context of a systemic maternal inflammatory response. *Journal of perinatal medicine* 2016;44:53–76. [PubMed: 26360486]
64. Romero R, Chaemsaithong P, Docheva N, Korzeniewski SJ, Kusanovic JP, Yoon BH, et al. Clinical chorioamnionitis at term VI: acute chorioamnionitis and funisitis according to the presence or absence of microorganisms and inflammation in the amniotic cavity. *Journal of perinatal medicine* 2016;44:33–51. [PubMed: 26352071]
65. Martinez-Varea A, Romero R, Xu Y, Miller D, Ahmed AI, Chaemsaithong P, et al. Clinical chorioamnionitis at term VII: the amniotic fluid cellular immune response. *Journal of perinatal medicine* 2017;45:523–38. [PubMed: 27763883]
66. Chaiyasit N, Romero R, Chaemsaithong P, Docheva N, Bhatti G, Kusanovic JP, et al. Clinical chorioamnionitis at term VIII: a rapid MMP-8 test for the identification of intra-amniotic inflammation. *Journal of perinatal medicine* 2017;45:539–50. [PubMed: 28672752]
67. Gomez-Lopez N, Romero R, Maymon E, Kusanovic JP, Panaitescu B, Miller D, et al. Clinical chorioamnionitis at term IX: in vivo evidence of intra-amniotic inflammasome activation. *J Perinat Med* 2018 11 9 [Epub ahead of print].
68. Gomez R, Romero R, Nien JK, Chaiworapongsa T, Medina L, Kim YM, et al. A short cervix in women with preterm labor and intact membranes: a risk factor for microbial invasion of the amniotic cavity. *Am J Obstet Gynecol* 2005;192:678–89. [PubMed: 15746658]
69. Romero R, Espinoza J, Rogers WT, Moser A, Nien JK, Kusanovic JP, et al. Proteomic analysis of amniotic fluid to identify women with preterm labor and intra-amniotic inflammation/infection: the use of a novel computational method to analyze mass spectrometric profiling. *J Matern Fetal Neonatal Med* 2008;21:367–88. [PubMed: 18570116]
70. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. *Lancet* 2008;371:75–84. [PubMed: 18177778]
71. Hassan S, Romero R, Hendler I, Gomez R, Khalek N, Espinoza J, et al. A sonographic short cervix as the only clinical manifestation of intra-amniotic infection. *Journal of perinatal medicine* 2006;34:13–9. [PubMed: 16489881]
72. Yoon BH, Romero R, Moon JB, Oh SY, Han SY, Kim JC, et al. The frequency and clinical significance of intra-amniotic inflammation in patients with a positive cervical fetal fibronectin. *Am J Obstet Gynecol* 2001;185:1137–42. [PubMed: 11717647]
73. Novy MJ, Duffy L, Axthelm MK, Sadowsky DW, Witkin SS, Gravett MG, et al. *Ureaplasma parvum* or *Mycoplasma hominis* as sole pathogens cause chorioamnionitis, preterm delivery, and fetal pneumonia in rhesus macaques. *Reprod Sci* 2009;16:56–70. [PubMed: 19122105]
74. Grigsby PL, Novy MJ, Sadowsky DW, Morgan TK, Long M, Acosta E, et al. Maternal azithromycin therapy for *Ureaplasma* intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. *Am J Obstet Gynecol* 2012;207:475 e1–e14. [PubMed: 23111115]
75. Witt A, Berger A, Gruber CJ, Petricevic L, Apfalter P, Husslein P. IL-8 concentrations in maternal serum, amniotic fluid and cord blood in relation to different pathogens within the amniotic cavity. *Journal of perinatal medicine* 2005;33:22–6. [PubMed: 15841609]

76. Horowitz S, Horowitz J, Mazor M, Porath A, Glezerman M. Ureaplasma urealyticum cervical colonization as a marker for pregnancy complications. *Int J Gynaecol Obstet* 1995;48:15–9. [PubMed: 7698376]
77. Abele-Horn M, Scholz M, Wolff C, Kolben M. High-density vaginal Ureaplasma urealyticum colonization as a risk factor for chorioamnionitis and preterm delivery. *Acta Obstet Gynecol Scand* 2000;79:973–8. [PubMed: 11081683]
78. Harada K, Tanaka H, Komori S, Tsuji Y, Nagata K, Tsutsui H, et al. Vaginal infection with Ureaplasma urealyticum accounts for preterm delivery via induction of inflammatory responses. *Microbiol Immunol* 2008;52:297–304. [PubMed: 18577163]
79. Breugelmans M, Vancutsem E, Naessens A, Laubach M, Foulon W. Association of abnormal vaginal flora and Ureaplasma species as risk factors for preterm birth: a cohort study. *Acta Obstet Gynecol Scand* 2010;89:256–60. [PubMed: 19943819]
80. Kwak DW, Hwang HS, Kwon JY, Park YW, Kim YH. Co-infection with vaginal Ureaplasma urealyticum and Mycoplasma hominis increases adverse pregnancy outcomes in patients with preterm labor or preterm premature rupture of membranes. *J Matern Fetal Neonatal Med* 2014;27:333–7. [PubMed: 23796000]
81. Donders GGG, Ruban K, Bellen G, Petricevic L. Mycoplasma/Ureaplasma infection in pregnancy: to screen or not to screen. *Journal of perinatal medicine* 2017;45:505–15. [PubMed: 28099135]
82. Carey JC, Blackwelder WC, Nugent RP, Matteson MA, Rao AV, Eschenbach DA, et al. Antepartum cultures for Ureaplasma urealyticum are not useful in predicting pregnancy outcome. The Vaginal Infections and Prematurity Study Group. *Am J Obstet Gynecol* 1991;164:728–33. [PubMed: 2003532]
83. Lee SE, Romero R, Kim EC, Yoon BH. A high Nugent score but not a positive culture for genital mycoplasmas is a risk factor for spontaneous preterm birth. *J Matern Fetal Neonatal Med* 2009;22:212–7. [PubMed: 19330704]
84. Ioannidis A, Papaioannou P, Magiorkinis E, Magana M, Ioannidou V, Tzanetou K, et al. Detecting the Diversity of Mycoplasma and Ureaplasma Endosymbionts Hosted by Trichomonas vaginalis Isolates. *Front Microbiol* 2017;8:1188. [PubMed: 28702014]
85. Nakai A, Taniuchi Y, Miyake H, Nakai M, Yokota A, Takeshita T. Increased level of granulocyte elastase in cervical secretion is an independent predictive factor for preterm delivery. *Gynecol Obstet Invest* 2005;60:87–91. [PubMed: 15809507]
86. Becher N, Adams Waldorf K, Hein M, Uldbjerg N. The cervical mucus plug: structured review of the literature. *Acta Obstet Gynecol Scand* 2009;88:502–13. [PubMed: 19330570]
87. Smith-Dupont KB, Wagner CE, Witten J, Conroy K, Rudoltz H, Pagidas K, et al. Probing the potential of mucus permeability to signify preterm birth risk. *Sci Rep* 2017;7:10302. [PubMed: 28871085]
88. Vornhagen J, Quach P, Santana-Ufret V, Alishetti V, Brokaw A, Armistead B, et al. Human Cervical Mucus Plugs Exhibit Insufficiencies in Antimicrobial Activity Towards Group B Streptococcus. *J Infect Dis* 2018;217:1626–36. [PubMed: 29425317]
89. Romero R, Miranda J, Chaiworapongsa T, Chaemsaitong P, Gotsch F, Dong Z, et al. Sterile intra-amniotic inflammation in asymptomatic patients with a sonographic short cervix: prevalence and clinical significance. *J Matern Fetal Neonatal Med* 2014:1–17 [Epub ahead of print].
90. Kiefer DG, Peltier MR, Keeler SM, Rust O, Ananth CV, Vintzileos AM, et al. Efficacy of midtrimester short cervix interventions is conditional on intraamniotic inflammation. *Am J Obstet Gynecol* 2016;214:276 e1–6. [PubMed: 26364833]
91. Tarca AL, Fitzgerald W, Chaemsaitong P, Xu Z, Hassan SS, Grivel JC, et al. The cytokine network in women with an asymptomatic short cervix and the risk of preterm delivery. *Am J Reprod Immunol* 2017;78:e12686.
92. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. *N Engl J Med* 1996;334:567–72. [PubMed: 8569824]
93. Iams JD, Goldenberg RL, Mercer BM, Moawad A, Thom E, Meis PJ, et al. The Preterm Prediction Study: recurrence risk of spontaneous preterm birth. National Institute of Child Health and Human

- Development Maternal-Fetal Medicine Units Network. *Am J Obstet Gynecol* 1998;178:1035–40. [PubMed: 9609580]
94. Goldenberg RL, Iams JD, Das A, Mercer BM, Meis PJ, Moawad AH, et al. The Preterm Prediction Study: sequential cervical length and fetal fibronectin testing for the prediction of spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. *Am J Obstet Gynecol* 2000;182:636–43. [PubMed: 10739521]
  95. Hibbard JU, Tart M, Moawad AH. Cervical length at 16–22 weeks' gestation and risk for preterm delivery. *Obstet Gynecol* 2000;96:972–8. [PubMed: 11084188]
  96. To MS, Skentou C, Cicero S, Liao AW, Nicolaides KH. Cervical length at 23 weeks in triplets: prediction of spontaneous preterm delivery. *Ultrasound Obstet Gynecol* 2000;16:515–8. [PubMed: 11169343]
  97. Hassan SS, Romero R, Berry SM, Dang K, Blackwell SC, Treadwell MC, et al. Patients with an ultrasonographic cervical length  $\leq$  15 mm have nearly a 50% risk of early spontaneous preterm delivery. *Am J Obstet Gynecol* 2000;182:1458–67. [PubMed: 10871466]
  98. Hadzi-Lega M, Markova AD, Stefanovic M, Tanturovski M. Correlation of cervical length, fetal fibronectin, pHIGFBP-1, and cytokines in spontaneous preterm birth up to 14 days from sampling. *Journal of perinatal medicine* 2015;43:545–51. [PubMed: 25503663]
  99. Nikolova T, Bayev O, Nikolova N, Di Renzo GC. Comparison of a novel test for placental alpha microglobulin-1 with fetal fibronectin and cervical length measurement for the prediction of imminent spontaneous preterm delivery in patients with threatened preterm labor. *Journal of perinatal medicine* 2015;43:395–402. [PubMed: 25562603]
  100. Conde-Agudelo A, Romero R. Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: clinical and public health implications. *Am J Obstet Gynecol* 2016;214:235–42. [PubMed: 26450404]
  101. Khalifeh A, Berghella V. Universal cervical length screening in singleton gestations without a previous preterm birth: ten reasons why it should be implemented. *Am J Obstet Gynecol* 2016;214:603 e1–5. [PubMed: 26707072]
  102. Melamed N, Pittini A, Hirsch L, Yogev Y, Korzeniewski SJ, Romero R, et al. Do serial measurements of cervical length improve the prediction of preterm birth in asymptomatic women with twin gestations? *Am J Obstet Gynecol* 2016;215:616 e1–e14. [PubMed: 27365003]
  103. Son M, Grobman WA, Ayala NK, Miller ES. A universal mid-trimester transvaginal cervical length screening program and its associated reduced preterm birth rate. *Am J Obstet Gynecol* 2016;214:365 e1–5. [PubMed: 26928150]
  104. Vintzileos AM, Visser GH. Interventions for women with mid-trimester short cervix: which ones work? *Ultrasound Obstet Gynecol* 2017;49:295–300. [PubMed: 28266160]
  105. Sharvit M, Weiss R, Ganor Paz Y, Tzadikvitch Geffen K, Danielli Miller N, Biron-Shental T. Vaginal examination vs. cervical length - which is superior in predicting preterm birth? *Journal of perinatal medicine* 2017;45:977–83. [PubMed: 28475099]
  106. Oturina V, Hammer K, Mollers M, Braun J, Falkenberg MK, de Murcia KO, et al. Assessment of cervical elastography strain pattern and its association with preterm birth. *Journal of perinatal medicine* 2017;45:925–32. [PubMed: 28258974]
  107. Hernandez-Andrade E, Maymon E, Luewan S, Bhatti G, Mehrmohammadi M, Erez O, et al. A soft cervix, categorized by shear-wave elastography, in women with short or with normal cervical length at 18–24 weeks is associated with a higher prevalence of spontaneous preterm delivery. *Journal of perinatal medicine* 2018;46:489–501. [PubMed: 29813033]
  108. Conde-Agudelo A, Romero R, Da Fonseca E, O'Brien JM, Cetingoz E, Creasy GW, et al. Vaginal progesterone is as effective as cervical cerclage to prevent preterm birth in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix: updated indirect comparison meta-analysis. *Am J Obstet Gynecol* 2018;219:10–25. [PubMed: 29630885]
  109. Sanchez-Ramos L. Vaginal progesterone is an alternative to cervical cerclage in women with a short cervix and a history of preterm birth. *Am J Obstet Gynecol* 2018;219:5–9. [PubMed: 29941278]
  110. Boelig RC, Berghella V. What's new in preterm birth prediction and prevention? *Journal of perinatal medicine* 2018;46:455–6. [PubMed: 29794253]


111. Shivani D, Quek BH, Tan PL, Shephali T. Does rescue cerclage work? *Journal of perinatal medicine* 2018;46:876–80. [PubMed: 29936490]
112. Daskalakis G, Zacharakis D, Theodora M, Antsaklis P, Papantoniou N, Loutradis D, et al. Safety and efficacy of the cervical pessary combined with vaginal progesterone for the prevention of spontaneous preterm birth. *Journal of perinatal medicine* 2018;46:531–7. [PubMed: 29055173]
113. Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. *Sci Transl Med* 2014;6:237ra65.
114. Prince AL, Ma J, Kannan PS, Alvarez M, Gisslen T, Harris RA, et al. The placental membrane microbiome is altered among subjects with spontaneous preterm birth with and without chorioamnionitis. *Am J Obstet Gynecol* 2016;214:627 e1–e16. [PubMed: 26965447]
115. Latino MA, Botta G, Badino C, Maria D, Petrozziello A, Sensini A, et al. Association between genital mycoplasmas, acute chorioamnionitis and fetal pneumonia in spontaneous abortions. *Journal of perinatal medicine* 2018;46:503–8. [PubMed: 28599391]
116. Cox C, Saxena N, Watt AP, Gannon C, McKenna JP, Fairley DJ, et al. The common vaginal commensal bacterium *Ureaplasma parvum* is associated with chorioamnionitis in extreme preterm labor. *J Matern Fetal Neonatal Med* 2016;29:3646–51. [PubMed: 26795404]
117. Oh KJ, Hong JS, Romero R, Yoon BH. The frequency and clinical significance of intra-amniotic inflammation in twin pregnancies with preterm labor and intact membranes. *J Matern Fetal Neonatal Med* 2019;32:527–41. [PubMed: 29020827]
118. Keelan JA. Intrauterine inflammatory activation, functional progesterone withdrawal, and the timing of term and preterm birth. *J Reprod Immunol* 2018;125:89–99. [PubMed: 29329080]
119. Moss TJ, Nitsos I, Ikegami M, Jobe AH, Newnham JP. Experimental intrauterine *Ureaplasma* infection in sheep. *Am J Obstet Gynecol* 2005;192:1179–86. [PubMed: 15846199]
120. Jacobsson B, Aaltonen R, Rantakokko-Jalava K, Morken NH, Alanen A. Quantification of *Ureaplasma urealyticum* DNA in the amniotic fluid from patients in PTL and pPROM and its relation to inflammatory cytokine levels. *Acta Obstet Gynecol Scand* 2009;88:63–70. [PubMed: 19031281]
121. von Chamier M, Allam A, Brown MB, Reinhard MK, Reyes L. Host genetic background impacts disease outcome during intrauterine infection with *Ureaplasma parvum*. *PLoS One* 2012;7:e44047. [PubMed: 22952869]
122. Modi BP, Teves ME, Pearson LN, Parikh HI, Haymond-Thornburg H, Tucker JL, et al. Mutations in fetal genes involved in innate immunity and host defense against microbes increase risk of preterm premature rupture of membranes (PPROM). *Mol Genet Genomic Med* 2017;5:720–9. [PubMed: 29178652]
123. Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in the human uterus during pregnancy and parturition. *Am J Obstet Gynecol* 1984;150:734–41. [PubMed: 6093538]
124. Bogacki M, Silvia WJ, Rekawiecki R, Kotwica J. Direct inhibitory effect of progesterone on oxytocin-induced secretion of prostaglandin F(2alpha) from bovine endometrial tissue. *Biol Reprod* 2002;67:184–8. [PubMed: 12080016]
125. Saji F, Samejima Y, Kamiura S, Sawai K, Shimoya K, Kimura T. Cytokine production in chorioamnionitis. *J Reprod Immunol* 2000;47:185–96. [PubMed: 10924750]
126. Mitchell BF, Schmid B. Oxytocin and its receptor in the process of parturition. *J Soc Gynecol Investig* 2001;8:122–33.
127. Schmid B, Wong S, Mitchell BF. Transcriptional regulation of oxytocin receptor by interleukin-1beta and interleukin-6. *Endocrinology* 2001;142:1380–5. [PubMed: 11250916]
128. Massrieh W, Derjuga A, Doualla-Bell F, Ku CY, Sanborn BM, Blank V. Regulation of the MAFF transcription factor by proinflammatory cytokines in myometrial cells. *Biol Reprod* 2006;74:699–705. [PubMed: 16371591]
129. Kimura T, Ivell R, Rust W, Mizumoto Y, Ogita K, Kusui C, et al. Molecular cloning of a human MafF homologue, which specifically binds to the oxytocin receptor gene in term myometrium. *Biochem Biophys Res Commun* 1999;264:86–92. [PubMed: 10527846]
130. Bethin KE, Nagai Y, Sladek R, Asada M, Sadovsky Y, Hudson TJ, et al. Microarray analysis of uterine gene expression in mouse and human pregnancy. *Mol Endocrinol* 2003;17:1454–69. [PubMed: 12775764]

131. Wathes DC, Borwick SC, Timmons PM, Leung ST, Thornton S. Oxytocin receptor expression in human term and preterm gestational tissues prior to and following the onset of labour. *J Endocrinol* 1999;161:143–51. [PubMed: 10194538]
132. Mazze RI, Kallen B. Appendectomy during pregnancy: a Swedish registry study of 778 cases. *Obstet Gynecol* 1991;77:835–40. [PubMed: 2030853]
133. Ibiebele I, Schnitzler M, Nippita T, Ford JB. Appendectomy during pregnancy and the risk of preterm birth: A population data linkage study. *Aust N Z J Obstet Gynaecol* 2019;59:45–53. [PubMed: 29602171]
134. Won RP, Friedlander S, Lee SL. Management and Outcomes of Appendectomy during Pregnancy. *Am Surg* 2017;83:1103–7. [PubMed: 29391104]
135. Abbasi N, Patenaude V, Abenhaim HA. Evaluation of obstetrical and fetal outcomes in pregnancies complicated by acute appendicitis. *Arch Gynecol Obstet* 2014;290:661–7. [PubMed: 24838290]
136. Millar LK, DeBuque L, Wing DA. Uterine contraction frequency during treatment of pyelonephritis in pregnancy and subsequent risk of preterm birth. *Journal of perinatal medicine* 2003;31:41–6. [PubMed: 12661143]
137. Farkash E, Weintraub AY, Sergienko R, Wiznitzer A, Zlotnik A, Sheiner E. Acute antepartum pyelonephritis in pregnancy: a critical analysis of risk factors and outcomes. *Eur J Obstet Gynecol Reprod Biol* 2012;162:24–7. [PubMed: 22381037]
138. Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. *Am J Obstet Gynecol* 2014;210:219 e1–6. [PubMed: 24100227]
139. Meijer WJ, van Noortwijk AG, Bruinse HW, Wensing AM. Influenza virus infection in pregnancy: a review. *Acta Obstet Gynecol Scand* 2015;94:797–819. [PubMed: 26012384]
140. Bayraktar MR, Ozerol IH, Gucluer N, Celik O. Prevalence and antibiotic susceptibility of *Mycoplasma hominis* and *Ureaplasma urealyticum* in pregnant women. *Int J Infect Dis* 2010;14:e90–5. [PubMed: 19515594]
141. Fell DB, Platt RW, Basso O, Wilson K, Kaufman JS, Buckeridge DL, et al. The Relationship Between 2009 Pandemic H1N1 Influenza During Pregnancy and Preterm Birth: A Population-based Cohort Study. *Epidemiology* 2018;29:107–16. [PubMed: 28930786]
142. Knowles SJ, O’Sullivan NP, Meenan AM, Hanniffy R, Robson M. Maternal sepsis incidence, aetiology and outcome for mother and fetus: a prospective study. *BJOG* 2015;122:663–71. [PubMed: 24862293]
143. Gomez R, Ghezzi F, Romero R, Munoz H, Tolosa JE, Rojas I. Premature labor and intra-amniotic infection. Clinical aspects and role of the cytokines in diagnosis and pathophysiology. *Clin Perinatol* 1995;22:281–342. [PubMed: 7671540]
144. Rodriguez N, Fernandez C, Zamora Y, Berdasquera D, Rivera JA. Detection of *Ureaplasma urealyticum* and *Ureaplasma parvum* in amniotic fluid: association with pregnancy outcomes. *J Matern Fetal Neonatal Med* 2011;24:47–50.
145. Gervasi MT, Romero R, Bracalente G, Erez O, Dong Z, Hassan SS, et al. Midtrimester amniotic fluid concentrations of interleukin-6 and interferon-gamma-inducible protein-10: evidence for heterogeneity of intra-amniotic inflammation and associations with spontaneous early (<32 weeks) and late (>32 weeks) preterm delivery. *Journal of perinatal medicine* 2012;40:329–43. [PubMed: 22752762]
146. Yoon BH, Jun JK, Park KH, Syn HC, Gomez R, Romero R. Serum C-reactive protein, white blood cell count, and amniotic fluid white blood cell count in women with preterm premature rupture of membranes. *Obstet Gynecol* 1996;88:1034–40. [PubMed: 8942849]
147. Dulay AT, Buhimschi IA, Zhao G, Bahtiyar MO, Thung SF, Cackovic M, et al. Compartmentalization of acute phase reactants Interleukin-6, C-Reactive Protein and Procalcitonin as biomarkers of intra-amniotic infection and chorioamnionitis. *Cytokine* 2015;76:236–43. [PubMed: 25957466]
148. Stepan M, Cobo T, Musilova I, Hornychova H, Jacobsson B, Kacerovsky M. Maternal Serum C-Reactive Protein in Women with Preterm Prelabor Rupture of Membranes. *PLoS One* 2016;11:e0150217. [PubMed: 26942752]




149. Gomez-Lopez N, Romero R, Xu Y, Leng Y, Garcia-Flores V, Miller D, et al. Are amniotic fluid neutrophils in women with intraamniotic infection and/or inflammation of fetal or maternal origin? *Am J Obstet Gynecol* 2017;217:693 e1–e16. [PubMed: 28964823]
150. Romero R, Miranda J, Chaiworapongsa T, Chaemsaihong P, Gotsch F, Dong Z, et al. A novel molecular microbiologic technique for the rapid diagnosis of microbial invasion of the amniotic cavity and intra-amniotic infection in preterm labor with intact membranes. *Am J Reprod Immunol* 2014;71:330–58. [PubMed: 24417618]

P=0.002 by Kruskal-Wallis analysis

**Figure 1.**

Amniotic fluid matrix metalloproteinase-8 concentrations according to gestational age at amniocentesis (i.e., -25.9 weeks, 26.0–33.9 weeks, and 34.0–36.9 weeks) in women with intra-amniotic infection by *Ureaplasma* spp. (median: 714.6 ng/mL, interquartile range [IQR]: 165.8–2681.2 ng/mL vs. median: 157.7 ng/mL, IQR: 24.9–870.8 ng/mL vs. median: 24.0 ng/mL, IQR: 1.8–272.3 ng/mL; P=.002 by Kruskal-Wallis analysis).



**Figure 2.** The frequency of intra-amniotic inflammation (defined as amniotic fluid matrix metalloproteinase-8 concentration > 23 ng/mL) according to the gestational age (P=0.002 by linear by linear association).

**Table 1.** Clinical characteristics and pregnancy outcomes according to gestational age at amniocentesis

Characteristics	Gestational age at amniocentesis			P value
	-25.9 weeks (n=17)	26-33.9 weeks (n=39)	34-36.9 weeks (n=15)	
Maternal age, years	31.5 ± 4.3	30.3 ± 3.6	29.1 ± 5.2	.390
Nulliparity	65% (6/17)	51% (20/39)	40% (6/15)	.492
Gestational age at amniocentesis, weeks	23.3 ± 2.9	30.3 ± 2.4	35.4 ± 0.6	<.001
Cervical dilatation, cm	0.5 ± 0.9	0.7 ± 0.8	2.2 ± 2.2	.017
Gestational age at delivery, weeks	25.0 ± 3.6	31.6 ± 2.3	35.5 ± 0.7	<.001
Birth weight, gram	742 ± 430	1645 ± 513	2441 ± 303	<.001
Male newborns <sup>a</sup>	67% (5/15)	62% (23/37)	43% (6/14)	.363
Cesarean delivery <sup>b</sup>	31% (5/16)	42% (16/38)	20% (3/15)	.297
Antenatal corticosteroids use	71% (12/17)	69% (27/39)	20% (3/15)	.002
Antenatal antibiotics use	100% (17/17)	97% (38/39)	87% (13/15)	.129
Clinical chorioamnionitis	12% (2/17)	5% (2/39)	0% (0/15)	.347

GA, gestational age.

Data was presents as mean ± standard deviation or % (n/N).

<sup>a</sup>Five cases with unavailable data were excluded from analysis.

<sup>b</sup>Two cases with unavailable data were excluded from analysis.

The amniotic fluid matrix metalloproteinase-8 concentration and amniotic white blood cell count according to gestational age at amniocentesis

**Table 2.**

Gestational age at amniocentesis (weeks)	Amniotic fluid matrix metalloproteinase-8 (ng/ml)	P-value <sup>a</sup>	Amniotic fluid white blood cell (cells/mm <sup>3</sup> )	P-value <sup>a</sup>
-25.9 (n=17)	714.6 (165.8–2681.2)	<.001	>1000 (384 – >1000)	.010
26.0–33.9 (n=39)	157.7 (24.9–870.8)		372 (22 – >1000)	
34.0–36.9 (n=15)	24.0 (1.8–272.3)		101 (3 – >1000)	

<sup>a</sup> Jonckheere–Terpstra test.

Values are given as median (interquartile range).

**Table 3.**

The maternal blood white blood cell count and serum C-reactive protein concentration according to gestational age at amniocentesis

Gestational age at amniocentesis (weeks)	Maternal blood white blood cell (cells/mm <sup>3</sup> )	P-value <sup>a</sup>	Maternal serum C-reactive protein (mg/dl)	P-value <sup>a</sup>
-25.9 (n=17)	13,730 (9845–17,890)	.186	1.3 (0.7–3.1)	.146
26.0–33.9 (n=39)	11,495 (9318–14,043)		0.5 (0.2–1.6)	
34.0–36.9 (n=15)	12,335 (8363–15,200)		0.9 (0.2–2.0)	

<sup>a</sup> Jonckheere–Terpstra test.

Values are given as median (interquartile range).

Correlation between amniotic fluid and maternal blood inflammatory markers and gestational age at amniocentesis

**Table 4.**

	Correlation coefficients in Spearman's rank correlation test	P value
Amniotic fluid		
Matrix metalloproteinase-8	-0.467	<.001
White blood cell count	-0.355	.003
Maternal blood		
C-reactive protein	-0.204	.103
White blood cell count	-0.247	.055

Table 5.

Neonatal outcome according to gestational age at amniocentesis

Characteristics	-25.9 weeks (n=16) <sup>a</sup>	26-33.9 weeks (n=37) <sup>b</sup>	34-36.9 weeks (n=15)	P-value
Birth weight	742 ± 430	1645 ± 513	2441 ± 303	<.001
Apgar score at 1 min <7	100% (16/16)	64.9% (24/37)	20.0% (3/15)	<.001
Apgar score at 5 min <7	81.3% (13/16)	16.2% (6/37)	0% (0/15)	<.001
Neonatal death	37.5% (6/16)	13.5% (5/37)	0% (0/15)	.015
Significant morbidity <sup>c</sup>	91.7% (11/12)	62.2% (23/37)	26.7% (4/15)	.003
Respiratory distress syndrome	41.7% (5/12)	18.9% (7/37)	0% (0/15)	.022
Bronchopulmonary dysplasia	72.7% (8/11)	18.8% (6/32)	0% (0/15)	<.001
Intraventricular hemorrhage	25.0% (3/12)	32.4% (12/37)	14.3% (2/14)	.422
Necrotizing enterocolitis	25.0% (3/12)	2.7% (1/37)	0% (0/15)	.011
Proven early neonatal sepsis	8.3% (1/12)	0% (0/37)	6.7% (1/15)	.236

<sup>a</sup>One case with unavailable data were excluded from analysis<sup>b</sup>Two cases with unavailable data were excluded from analysis<sup>c</sup>Four neonates who died *in utero* or immediately after birth because of extreme prematurity and thus could not be evaluated with respect to the presence or absence of complications were excluded from the analysis.